首页> 外文期刊>Frontiers in Pharmacology >LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
【24h】

LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain

机译:LPM580098是5-羟色胺,去甲肾上腺素和多巴胺的新型三重再摄取抑制剂,可减轻神经性疼痛。

获取原文
           

摘要

Background and Purpose: Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g., pregabalin, duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT), noradrenaline (NE), and dopamine (DA) play important roles in modulating the descending inhibitory pain pathway and sleep–wake cycle. The aim of this work was to test the hypothesis that LPM580098, a novel triple reuptake inhibitor (TRI) of 5-HT, NE, and DA, has analgesic effect, and does not induce significant adverse effects associated with central inhibition, such as sedation and somnolence. Methods: The analgesic activity of LPM580098 was assessed on formalin test and spinal nerve ligation (SNL)-induced neuropathic pain model. Locomotor activity, pentobarbital sodium-induced sleeping and rota-rod tests were also conducted. In vitro binding and uptake assays, and Western blotting were performed to examine the potential mechanisms. Results: LPM580098 suppressed the nocifensive behaviors during phase II of the formalin test in mice. In SNL rats, LPM580098 (16 mg kg ~(?1)) inhibited mechanical allodynia, thermal hyperalgesia and hyperexcitation of wide-dynamic range (WDR) neurons, in which the effect of LPM580098 was similar to pregabalin (30 mg kg ~(?1)). However, pregabalin altered the spontaneous locomotion, affected pentobarbital sodium-induced sleep, and showed a trend to perform motor dysfunction, which were not induced by LPM580098. Mechanistically, LPM580098 inhibited the uptake of 5-HT, NE, and DA, improved pain-induced changes of the synaptic functional plasticity and structural plasticity possibly via downregulating the NR2B/CaMKIIα/GluR1 and Rac1/RhoA signaling pathways. Conclusion: Our results suggest that LPM580098, a novel TRI, is effective in attenuating neuropathic pain without producing unwanted sedation and somnolence associated with central nervous system (CNS) depressants.
机译:背景和目的:镇静和清醒仍然是现有镇痛药(例如普瑞巴林,度洛西汀)对神经性疼痛的严重不利影响。现有证据表明,血清素(5-HT),去甲肾上腺素(NE)和多巴胺(DA)在调节抑制性疼痛途径和睡眠-觉醒周期中起着重要作用。这项工作的目的是检验以下假设:LPM580098是5-HT,NE和DA的新型三重再摄取抑制剂(TRI)具有镇痛作用,并且不会引起与中枢抑制有关的重大不良反应,例如镇静作用和嗜睡。方法:通过福尔马林测试和脊髓神经结扎(SNL)诱发的神经性疼痛模型评估LPM580098的镇痛活性。还进行了运动活动,戊巴比妥钠诱发的睡眠和旋转棒测试。进行体外结合和摄取测定以及蛋白质印迹以检查潜在的机制。结果:LPM580098在福尔马林试验的II期小鼠中抑制了伤害行为。在SNL大鼠中,LPM580098(16 mg kg〜(?1))抑制了机械痛觉过敏,热痛觉过敏和宽动态范围(WDR)神经元的过度兴奋,其中LPM580098的作用类似于普瑞巴林(30 mg kg〜(?1))。 1))。然而,普瑞巴林改变了自发运动,影响了戊巴比妥钠诱发的睡眠,并表现出执行运动功能障碍的趋势,而LPM580098并未诱发这种运动障碍。在机制上,LPM580098可能通过下调NR2B /CaMKIIα/ GluR1和Rac1 / RhoA信号通路来抑制5-HT,NE和DA的摄取,改善疼痛诱导的突触功能可塑性和结构可塑性的变化。结论:我们的结果表明,新型TRI LPM580098可有效减轻神经性疼痛,而不会产生与中枢神经系统(CNS)抑制剂相关的镇静作用和嗜睡感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号